A food-grade engineered Lactococcus lactis strain delivering Helicobacter pylori Lpp20 alleviates bacterial infection in H. pylori-challenged mice

Sun, Nan; Zhang, Rongguang; Peng, Xiaoyan; Wang, Chen; Chen, Shuaiyin; Fan, Qi-Wen

doi:10.1007/s10529-019-02740-z

Cited by 5 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral administration of the engineered bacteria increased serum IgG and decreased gastric urease activity in mice. 106 …”

Section: Antigensmentioning

confidence: 99%

How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans?

Li¹,

Zhao²,

Xia³

et al. 2023

IDR

View full text Add to dashboard Cite

Helicobacter pylori infection often occurs in early childhood, and can last a lifetime if not treated with medication. H. pylori infection can also cause a variety of stomach diseases, which can only be treated with a combination of antibiotics. Combinations of antibiotics can cure H. pylori infection, but it is easy to relapse and develop drug resistance. Therefore, a vaccine is a promising strategy for prevention and therapy for the infection of H. pylori . After decades of research and development, there has been no appearance of any H. pylori vaccine reaching the market, unfortunately. This review summarizes the aspects of candidate antigens, immunoadjuvants, and delivery systems in the long journey of H. pylori vaccine research, and also introduces some clinical trials that have displayed encouraging or depressing results. Possible reasons for the inability of an H. pylori vaccine to be available over the counter are cautiously discussed and some propositions for the future of H. pylori vaccines are outlined.

show abstract

“…Oral administration of the engineered bacteria increased serum IgG and decreased gastric urease activity in mice. 106 …”

Section: Antigensmentioning

confidence: 99%

How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans?

Li¹,

Zhao²,

Xia³

et al. 2023

IDR

View full text Add to dashboard Cite

show abstract

“…This vaccine is therefore immunogenic and able to induce mucosal responses 37 . Mice orally immunised with recombinant L lactis expressing H pylori Lpp20 antigen 38 also had elevated serum IgG levels and reduced gastric urease activity following H pylori challenges.…”

Section: Vaccinesmentioning

confidence: 99%

Review ‐ Helicobacter, inflammation, immunology and vaccines

Robinson

Lehours

2020

Helicobacter

View full text Add to dashboard Cite

Understanding the mechanisms involved in induction and regulation of the immune and inflammatory response to Helicobacter pylori is extremely important in determining disease outcomes. H pylori expresses a plethora of factors that influence the host response. Vaccines against H pylori are desperately needed for the prevention of gastric carcinogenesis, especially with the increasing trends in antimicrobial resistance. This review summarizes some important findings, published between 1 April 2019 and 31 March 2020, in the areas of H pylori‐mediated inflammation, immunity and vaccines.

show abstract

Construction of a recombinant food-grade Lactococcus lactis expressing P23 protein of Cryptosporidium parvum

Liu

Deng

et al. 2022

Folia Microbiol

View full text Add to dashboard Cite

A food-grade engineered Lactococcus lactis strain delivering Helicobacter pylori Lpp20 alleviates bacterial infection in H. pylori-challenged mice

Cited by 5 publications

References 12 publications

How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans?

How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans?

Review ‐ Helicobacter, inflammation, immunology and vaccines

Construction of a recombinant food-grade Lactococcus lactis expressing P23 protein of Cryptosporidium parvum

Contact Info

Product

Resources

About